Ontology highlight
ABSTRACT:
SUBMITTER: Samant TS
PROVIDER: S-EPMC6099197 | biostudies-literature | 2018 Aug
REPOSITORIES: biostudies-literature
Samant Tanay S TS Dhuria Shyeilla S Lu Yasong Y Laisney Marc M Yang Shu S Grandeury Arnaud A Mueller-Zsigmondy Martin M Umehara Kenichi K Huth Felix F Miller Michelle M Germa Caroline C Elmeliegy Mohamed M
Clinical pharmacology and therapeutics 20171208 2
Ribociclib (KISQALI), a cyclin-dependent kinase 4/6 inhibitor approved for the first-line treatment of HR+/HER2- advanced breast cancer with an aromatase inhibitor, is administered with no restrictions on concomitant gastric pH-elevating agents or food intake. The influence of proton pump inhibitors (PPIs) on ribociclib bioavailability was assessed using 1) biorelevant media solubility, 2) physiologically based pharmacokinetic (PBPK) modeling, 3) noncompartmental analysis (NCA) of clinical trial ...[more]